United States warns people over blood infusions 'to try and slow ageing'

Plasma infusions from young blood donors have been promoted to treat a variety of conditions

Plasma infusions from young blood donors have been promoted to treat a variety of conditions

Ambrosia's website was updated Tuesday to say it has "ceased patient treatments" in compliance with the FDA's advisory.

According to representatives of the Ministry, proven clinical benefit from transfusion of blood plasma from young donors for treatment, mitigation or prevention of these conditions is not, however, there are risks associated with the use of any products based on plasma.

The FDA warned consumers against infusions of plasma from young donors, saying there is no evidence that they slow aging or memory loss.

The FDA said it'll monitor the issue and take appropriate steps with state and local health departments and blood establishments.

We recommend that you check out Huffington Post's investigation into Ambrosia, "a startup that sells young plasma treatments that offer numerous alleged potential benefits".

Those claims, however - and any other information about Ambrosia Health - have been scrubbed from the website.

Young-blood transfusions typically involve plasma, the fluid part of blood packed with signaling proteins and other molecules but no red or white cells. Transfusions with plasma can be lifesaving for people who experience physical trauma or who have certain diseases or conditions that prevent their blood from clotting properly.

Trump picks ambassador to Canada Kelly Craft as nominee for UN post
If confirmed for the role, Craft will succeed Nikki Haley , who abruptly announced her resignation in October a year ago . Her husband, Joe Craft, is president and chief executive of coal producer Alliance Resource Partners.

A 2017 clinical trial found that young blood transfusions did nearly nothing to treat Alzheimer. Gottlieb says he doesn't want the treatment to "discourage patients suffering from serious or intractable illnesses from receiving safe and effective treatments that may be available to them".

While the FDA did not name Ambrosia in its release, it cautioned consumers that there is "no proven clinical benefit" to the transfusions.

Ambrosia, the best known company providing infusions of blood plasma from younger donors, chose to stop treating patients following FDA's warning.

The plasma infusion trial was not performed under the Investigational New Drug (IND) program.

"Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimer's or Parkinson's disease", the statement read. Some "bad actors" have gone as far as charging thousands of dollars for these young-blood infusions. But as Live Science's Rachael Rettner reports, the Food and Drug Administration has raised the alarm about companies that purport to use blood plasma-specifically the blood of young donors-to combat the effects of aging and several severe ailments.

FDA approval of a treatment typically requires human trials before companies can make a specific health claim about a product. Nevertheless, said Drs. Gottlieb and Marks in a statement, "We're concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies".

Latest News